Skip to main content
Journal ArticleOPEN ACCESS

Longitudinal Immune Response to 3 Doses of Messenger RNA Vaccine Against Coronavirus Disease 2019 (COVID-19) in Pediatric Patients Receiving Chemotherapy for Cancer

Clinical Infectious Diseases (2023) 76(3) E510-E513
DOI: 10.1093/cid/ciac570
15Citations
Citations of this article
37Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Our study in 21 pediatric cancer patients demonstrates that 3 doses of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) messenger RNA vaccine (BioNTech/Pfizer) elicited both humoral and cellular immunity in most patients during chemotherapy. Immunity was stronger in children with solid tumors and during maintenance therapy compared to those with hematological malignancies or during intensive chemotherapy.

Author supplied keywords

Cite

CITATION STYLE

APA

Lehrnbecher, T., Sack, U., Speckmann, C., Groll, A. H., Boldt, A., Siebald, B., … Hoehl, S. (2023). Longitudinal Immune Response to 3 Doses of Messenger RNA Vaccine Against Coronavirus Disease 2019 (COVID-19) in Pediatric Patients Receiving Chemotherapy for Cancer. Clinical Infectious Diseases, 76(3), E510–E513. https://doi.org/10.1093/cid/ciac570

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free